Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012-2015.

Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF.

Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.01814-18. doi: 10.1128/AAC.01814-18. [Epub ahead of print]

PMID:
30670424
2.

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-Abdominal Infections, Complicated Urinary Tract Infections and Nosocomial Pneumonia.

Das S, Li J, Riccobene T, Carrothers TJ, Newell P, Melnick D, Critchley IA, Stone GG, Nichols WW.

Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.02187-18. doi: 10.1128/AAC.02187-18. [Epub ahead of print] Review.

PMID:
30670413
3.

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.

Das S, Li J, Iaconis J, Zhou D, Stone GG, Yan JL, Melnick D.

J Antimicrob Chemother. 2019 Feb 1;74(2):425-431. doi: 10.1093/jac/dky439.

4.

In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.

Kazmierczak KM, Bradford PA, Stone GG, de Jonge BLM, Sahm DF.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e00592-18. doi: 10.1128/AAC.00592-18. Print 2018 Dec.

PMID:
30249690
5.

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.

Nichols WW, Stone GG, Newell P, Broadhurst H, Wardman A, MacPherson M, Yates K, Riccobene T, Critchley IA, Das S.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e02590-17. doi: 10.1128/AAC.02590-17. Print 2018 Nov.

PMID:
30061279
6.

In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.

Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF.

J Antimicrob Chemother. 2018 Oct 1;73(10):2777-2781. doi: 10.1093/jac/dky267.

PMID:
30010951
7.

In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15.

Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF.

J Antimicrob Chemother. 2018 Oct 1;73(10):2782-2788. doi: 10.1093/jac/dky266.

PMID:
30010894
8.

Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.

Stone GG, Newell P, Gasink LB, Broadhurst H, Wardman A, Yates K, Chen Z, Song J, Chow JW.

J Antimicrob Chemother. 2018 Sep 1;73(9):2519-2523. doi: 10.1093/jac/dky204.

PMID:
29912399
9.

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02569-17. doi: 10.1128/AAC.02569-17. Print 2018 Jul.

10.

A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.

Bradford PA, Huband MD, Stone GG.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00223-18. doi: 10.1128/AAC.00223-18. Print 2018 Jul.

11.

In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections.

Stone GG, Newell P, Bradford PA.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02584-17. doi: 10.1128/AAC.02584-17. Print 2018 Jul.

12.

Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.

Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK.

Int J Antimicrob Agents. 2018 Aug;52(2):287-292. doi: 10.1016/j.ijantimicag.2018.04.001. Epub 2018 Apr 11.

PMID:
29654893
13.

Prevalence of mcr-type genes among colistin-resistant Enterobacteriaceae collected in 2014-2016 as part of the INFORM global surveillance program.

Wise MG, Estabrook MA, Sahm DF, Stone GG, Kazmierczak KM.

PLoS One. 2018 Apr 2;13(4):e0195281. doi: 10.1371/journal.pone.0195281. eCollection 2018.

14.

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.

Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK, Jones RN.

J Clin Microbiol. 2018 May 25;56(6). pii: e01960-17. doi: 10.1128/JCM.01960-17. Print 2018 Jun.

15.

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.

Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, Song J, Taylor D, Laud PJ, Stone GG, Chow JW.

Lancet Infect Dis. 2018 Mar;18(3):285-295. doi: 10.1016/S1473-3099(17)30747-8. Epub 2017 Dec 16.

16.

Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK).

Woodford N, Xu-McCrae L, Mushtaq S, Wu HHT, Ellington MJ, Lancaster O, Davies F, Donaldson H, Rao GG, Verma A, Wareham DW, Ciesielczuk H, Stone GG, Irani PM, Bracher S, Hawkey PM.

J Antimicrob Chemother. 2018 Mar 1;73(3):698-702. doi: 10.1093/jac/dkx471.

PMID:
29253163
17.

Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

Mitton-Fry MJ, Brickner SJ, Hamel JC, Barham R, Brennan L, Casavant JM, Ding X, Finegan S, Hardink J, Hoang T, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Subramanyam C, Plotkin M, Reilly U, Schafer J, Stone GG, Uccello DP, Wisialowski T, Yoon K, Zaniewski R, Zook C.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3353-3358. doi: 10.1016/j.bmcl.2017.06.009. Epub 2017 Jun 3.

PMID:
28610977
18.

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.

Qin X, Tran BG, Kim MJ, Wang L, Nguyen DA, Chen Q, Song J, Laud PJ, Stone GG, Chow JW.

Int J Antimicrob Agents. 2017 May;49(5):579-588. doi: 10.1016/j.ijantimicag.2017.01.010. Epub 2017 Mar 29.

19.
20.

In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.

Stone GG, Bradford PA, Yates K, Newell P.

J Antimicrob Chemother. 2017 May 1;72(5):1396-1399. doi: 10.1093/jac/dkw561.

PMID:
28088768
21.
22.

New Antimicrobial Agents  …  but No Susceptibility Tests!

Ambler JE, Krause KM, Steenbergen JN, Scangarella-Oman NE, Miller LA, Bhagwat SS, Serio AW, Chesnel L, Mahoney NM, Motyl MR, Critchley IA, Iaconis JP, Stone GG, Alder J, Xerri L, McCurdy SP, van Veenhuyzen DF, Grossman T, Echols RM, Williams G, Bradford PA.

Clin Infect Dis. 2016 Dec 1;63(11):1530-1531. Epub 2016 Aug 31. No abstract available.

PMID:
27581762
23.

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.

Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB.

Clin Infect Dis. 2016 Sep 15;63(6):754-762. doi: 10.1093/cid/ciw378. Epub 2016 Jun 16.

24.

Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.

Hackel M, Kazmierczak KM, Hoban DJ, Biedenbach DJ, Bouchillon SK, de Jonge BL, Stone GG.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4677-83. doi: 10.1128/AAC.02841-15. Print 2016 Aug.

25.

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.

Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J.

Clin Infect Dis. 2016 Jun 1;62(11):1380-1389. doi: 10.1093/cid/ciw133. Epub 2016 Mar 8.

26.

Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.

Karlowsky JA, Biedenbach DJ, Kazmierczak KM, Stone GG, Sahm DF.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2849-57. doi: 10.1128/AAC.02286-15. Print 2016 May.

27.

β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates.

Mendes RE, Castanheira M, Gasink L, Stone GG, Nichols WW, Flamm RK, Jones RN.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1328-35. doi: 10.1128/AAC.01173-15.

28.

NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.

Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE.

Antimicrob Agents Chemother. 2014 May;58(5):2657-64. doi: 10.1128/AAC.02778-13. Epub 2014 Feb 24. Erratum in: Antimicrob Agents Chemother. 2014 Jul;58(7):4250.

29.

Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value.

Flamm RK, Stone GG, Sader HS, Jones RN, Nichols WW.

J Chemother. 2014 Dec;26(6):333-8. doi: 10.1179/1973947813Y.0000000145. Epub 2013 Dec 6.

PMID:
24125508
30.

Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

Mitton-Fry MJ, Brickner SJ, Hamel JC, Brennan L, Casavant JM, Chen M, Chen T, Ding X, Driscoll J, Hardink J, Hoang T, Hua E, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Plotkin M, Reilly U, Robinson S, Schafer J, Shepard RM, Smith JF, Stone GG, Subramanyam C, Yoon K, Yuan W, Zaniewski RP, Zook C.

Bioorg Med Chem Lett. 2013 May 15;23(10):2955-61. doi: 10.1016/j.bmcl.2013.03.047. Epub 2013 Mar 21.

PMID:
23566517
31.

The discovery and structure-activity relationships leading to CE-156811, a difluorophenyl cyclopropyl fluoroether: a novel potent antibacterial analog derived from hygromycin A.

Le PT, Brickner SJ, Wade SK, Brighty K, Monahan R, Stone GG, Girard D, Finegan S, Duignan J, Schafer J, Maloney M, Zaniewski RP, Connolly AG, Liras J, Bordner J, Samardjiev I.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):276-9. doi: 10.1016/j.bmcl.2010.11.022. Epub 2010 Nov 10.

PMID:
21115249
32.

Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections.

Magee TV, Ripp SL, Li B, Buzon RA, Chupak L, Dougherty TJ, Finegan SM, Girard D, Hagen AE, Falcone MJ, Farley KA, Granskog K, Hardink JR, Huband MD, Kamicker BJ, Kaneko T, Knickerbocker MJ, Liras JL, Marra A, Medina I, Nguyen TT, Noe MC, Obach RS, O'Donnell JP, Penzien JB, Reilly UD, Schafer JR, Shen Y, Stone GG, Strelevitz TJ, Sun J, Tait-Kamradt A, Vaz AD, Whipple DA, Widlicka DW, Wishka DG, Wolkowski JP, Flanagan ME.

J Med Chem. 2009 Dec 10;52(23):7446-57. doi: 10.1021/jm900729s.

PMID:
19775168
33.

The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus.

Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, des Etages SA, Jones A, Palazzolo-Ballance AM, Perdreau-Remington F, Sensabaugh GF, DeLeo FR, Chambers HF.

J Infect Dis. 2008 Jun 1;197(11):1523-30. doi: 10.1086/587907.

PMID:
18700257
34.

In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.

Stone GG, Girard D, Finegan S, Duignan J, Schafer J, Maloney M, Zaniewski RP, Brickner SJ, Wade SK, Le PT, Huband MD.

Antimicrob Agents Chemother. 2008 Jul;52(7):2663-6. doi: 10.1128/AAC.01326-07. Epub 2008 Apr 21.

35.

Design, synthesis and structure-activity relationships of 6-O-arylpropargyl diazalides with potent activity against multidrug-resistant Streptococcus pneumoniae.

Yong H, Gu YG, Clark RF, Marron T, Ma Z, Soni N, Stone GG, Nilius AM, Marsh K, Djuric SW.

Bioorg Med Chem Lett. 2005 May 16;15(10):2653-8. Erratum in: Bioorg Med Chem Lett. 2005 Jul 1;15(13):3313-4.

PMID:
15863336
36.

Synthesis and antibacterial activity of novel bifunctional macrolides.

Akritopoulou-Zanze I, Phelan KM, Marron TG, Yong H, Ma Z, Stone GG, Daly MM, Hensey DM, Nilius AM, Djuric SW.

Bioorg Med Chem Lett. 2004 Jul 16;14(14):3809-13.

PMID:
15203167
37.

Synthesis and antibacterial activity of 6-O-arylbutynyl ketolides with improved activity against some key erythromycin-resistant pathogens.

Keyes RF, Carter JJ, Englund EE, Daly MM, Stone GG, Nilius AM, Ma Z.

J Med Chem. 2003 May 8;46(10):1795-8.

PMID:
12723941
38.

PCR-oligonucleotide ligation assay for detection of point mutations associated with quinolone resistance in Streptococcus pneumoniae.

Bui MH, Stone GG, Nilius AM, Almer L, Flamm RK.

Antimicrob Agents Chemother. 2003 Apr;47(4):1456-9.

39.

Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus.

Almer LS, Shortridge VD, Nilius AM, Beyer JM, Soni NB, Bui MH, Stone GG, Flamm RK.

Diagn Microbiol Infect Dis. 2002 Jul;43(3):225-32.

PMID:
12106956
40.

Immunogenicity of chi4127 phoP- Salmonella enterica serovar Typhimurium in dogs.

McVey DS, Chengappa MM, Mosier DE, Stone GG, Oberst RD, Sylte MJ, Gabbert NM, Kelly-Aehle SM, Curtiss R.

Vaccine. 2002 Feb 22;20(11-12):1618-23.

PMID:
11858870
41.

Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance.

Versalovic J, Osato MS, Spakovsky K, Dore MP, Reddy R, Stone GG, Shortridge D, Flamm RK, Tanaka SK, Graham DY.

J Antimicrob Chemother. 1997 Aug;40(2):283-6.

PMID:
9301997
42.

PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial.

Stone GG, Shortridge D, Flamm RK, Beyer J, Ghoneim AT, Tanaka SK.

J Antimicrob Chemother. 1997 Aug;40(2):251-6.

PMID:
9301991
43.

PCR-RFLP typing of ureC from Helicobacter pylori isolated in Argentina from gastric biopsies before and after treatment with clarithromycin.

Stone GG, Shortridge D, Flamm RK, Beyer J, Stamler D, Tanaka SK.

Epidemiol Infect. 1997 Apr;118(2):119-24.

44.

A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori.

Stone GG, Shortridge D, Versalovic J, Beyer J, Flamm RK, Graham DY, Ghoneim AT, Tanaka SK.

Antimicrob Agents Chemother. 1997 Mar;41(3):712-4.

45.

Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism.

Shortridge VD, Stone GG, Flamm RK, Beyer J, Versalovic J, Graham DW, Tanaka SK.

J Clin Microbiol. 1997 Feb;35(2):471-3. Erratum in: J Clin Microbiol 1998 May;36(5):1468.

46.

Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori.

Stone GG, Shortridge D, Flamm RK, Versalovic J, Beyer J, Idler K, Zulawinski L, Tanaka SK.

Helicobacter. 1996 Dec;1(4):227-8.

PMID:
9432314
47.

Combined PCR-oligonucleotide ligation assay for rapid detection of Salmonella serovars.

Stone GG, Oberst RD, Hays MP, McVey S, Chengappa MM.

J Clin Microbiol. 1995 Nov;33(11):2888-93.

48.

Detection of Salmonella typhimurium from rectal swabs of experimentally infected beagles by short cultivation and PCR-hybridization.

Stone GG, Oberst RD, Hays MP, McVey S, Galland JC, Curtiss R 3rd, Kelly SM, Chengappa MM.

J Clin Microbiol. 1995 May;33(5):1292-5.

49.

Conjunctival microbial flora of clinically normal pigs.

Davidson HJ, Rogers DP, Yeary TJ, Stone GG, Schoneweis DA, Chengappa MM.

Am J Vet Res. 1994 Jul;55(7):949-51.

PMID:
7978633
50.

Detection of Salmonella serovars from clinical samples by enrichment broth cultivation-PCR procedure.

Stone GG, Oberst RD, Hays MP, McVey S, Chengappa MM.

J Clin Microbiol. 1994 Jul;32(7):1742-9.

Supplemental Content

Loading ...
Support Center